Pirfenidone Sensitizes Hepatic Stellate Cells to Ferroptosis by Reprogramming Glutamine and Serine Metabolism for GSH Depletion

Pirfenidone (PFD) shows therapeutic potential for liver fibrosis, but its molecular mechanisms are not fully elucidated. Activation of hepatic stellate cells (HSCs) is central to liver fibrosis, making their targeted elimination a prime therapeutic strategy. Since amino acid metabolism governs both...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Jia Li, Li Wang, Yakun Li, Junyu Wang, Manon Buist-Homan, Klaas Nico Faber, Han Moshage
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2026-04-01
Edice:	Antioxidants
Témata:	pirfenidone hepatic stellate cell liver fibrosis metabolic reprogramming ferroptosis
On-line přístup:	https://www.mdpi.com/2076-3921/15/5/552
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!